These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 26547049)

  • 1. Comparing the cost-effectiveness of four novel risk markers for screening asymptomatic individuals to prevent cardiovascular disease (CVD) in the US population.
    van Kempen BJ; Ferket BS; Steyerberg EW; Max W; Myriam Hunink MG; Fleischmann KE
    Int J Cardiol; 2016 Jan; 203():422-31. PubMed ID: 26547049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease.
    Špacírová Z; Kaptoge S; García-Mochón L; Rodríguez Barranco M; Sánchez Pérez MJ; Bondonno NP; Tjønneland A; Weiderpass E; Grioni S; Espín J; Sacerdote C; Schiborn C; Masala G; Colorado-Yohar SM; Kim L; Moons KGM; Engström G; Schulze MB; Bresson L; Moreno-Iribas C; Epstein D
    Eur J Health Econ; 2023 Sep; 24(7):1033-1045. PubMed ID: 36239877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canadian Cost-Effectiveness of Coronary Artery Calcium Screening Based on the Multi-Ethnic Study of Atherosclerosis.
    Qureshi H; Kaul P; Dover DC; Blaha MJ; Bellows BK; Mancini GBJ
    JACC Adv; 2024 Apr; 3(4):100886. PubMed ID: 38939688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for future cardiovascular disease using age alone compared with multiple risk factors and age.
    Wald NJ; Simmonds M; Morris JK
    PLoS One; 2011 May; 6(5):e18742. PubMed ID: 21573224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness evaluation of a high-sensitivity troponin I guided voluntary cardiovascular risk assessment program for asymptomatic women in Croatia.
    Krstačić G; Jülicher P; Krstačić A; Varounis C
    Int J Cardiol Cardiovasc Risk Prev; 2024 Mar; 20():200244. PubMed ID: 38476975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating subject-level incremental values of new markers for risk classification rule.
    Cai T; Tian L; Lloyd-Jones D; Wei LJ
    Lifetime Data Anal; 2013 Oct; 19(4):547-67. PubMed ID: 23807696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should adults with type 2 diabetes be screened for atherosclerotic cardiovascular disease?
    Zhao Y; Wong N
    F1000Res; 2015; 4():. PubMed ID: 26937273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Prevention for Intermediate Risk: The More Things Change, the More They Stay the Same.
    Greenland P; Glynn PA
    JACC Adv; 2024 Apr; 3(4):100884. PubMed ID: 38939677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressants are not overprescribed for mild depression.
    Simon GE; Rossom RC; Beck A; Waitzfelder BE; Coleman KJ; Stewart C; Operskalski B; Penfold RB; Shortreed SM
    J Clin Psychiatry; 2015 Dec; 76(12):1627-32. PubMed ID: 26580702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of Ectopic Fat Deposition: The Next Frontier in Serum Lipidomics.
    Perreault L; Starling AP; Glueck D; Brozinick JT; Sanders P; Siddall P; Kuo MS; Dabelea D; Bergman BC
    J Clin Endocrinol Metab; 2016 Jan; 101(1):176-82. PubMed ID: 26574956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: A Systematic Review.
    Oude Wolcherink MJ; Behr CM; Pouwels XGLV; Doggen CJM; Koffijberg H
    Pharmacoeconomics; 2023 Oct; 41(10):1183-1203. PubMed ID: 37328633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary calcium scoring for guiding lipid-lowering therapy is cost-effective: time to remove barriers to its use.
    Tasdighi E; Blaha MJ
    Med J Aust; 2023 Mar; 218(5):214-215. PubMed ID: 36811155
    [No Abstract]   [Full Text] [Related]  

  • 13. Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations.
    Behr CM; Oude Wolcherink MJ; IJzerman MJ; Vliegenthart R; Koffijberg H
    Pharmacoeconomics; 2023 Apr; 41(4):395-411. PubMed ID: 36670332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Using the Coronary Artery Calcium Score in Guiding Therapeutic Decisions in Primary Prevention in the Brazilian Population.
    Valério RS; Generoso G; Fernandes JL; Nasir K; Hong JC; Bittencourt MS
    Arq Bras Cardiol; 2022; 118(6):1126-1131. PubMed ID: 35703651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Model for Predicting the Presence of Coronary Artery Calcification.
    Park S; Hong M; Lee H; Cho NJ; Lee EY; Lee WY; Rhee EJ; Gil HW
    J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33503990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Coronary Calcium Score to Identify Candidates for ASCVD Prevention.
    Nguyen HL; Liu J; Del Castillo M; Shah T
    Curr Atheroscler Rep; 2019 Nov; 21(12):53. PubMed ID: 31754800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary Calcium Score and Cardiovascular Risk.
    Greenland P; Blaha MJ; Budoff MJ; Erbel R; Watson KE
    J Am Coll Cardiol; 2018 Jul; 72(4):434-447. PubMed ID: 30025580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The art of cardiovascular risk assessment.
    Khambhati J; Allard-Ratick M; Dhindsa D; Lee S; Chen J; Sandesara PB; O'Neal W; Quyyumi AA; Wong ND; Blumenthal RS; Sperling LS
    Clin Cardiol; 2018 May; 41(5):677-684. PubMed ID: 29746005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test.
    Itoga NK; Minami HR; Chelvakumar M; Pearson K; Mell MM; Bendavid E; Owens DK
    Vasc Med; 2018 Apr; 23(2):97-106. PubMed ID: 29345540
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.